Application of LiMgPO4 crystal for proton beam quality control in radiotherapy.

The radioluminescence (RL) emitted by LiMgPO4 detector under proton beam irradiation was investigated in real time at the radiotherapy facility in the Institute of Nuclear Physics Polish Academy of Sciences in Krakow. The facility uses protons accelerated by the AIC-144 isochronous cyclotron up to the energy of 60 MeV. The measurements of RL were carried out using a remote optical fiber device with a luminophore detector and photomultiplier located at opposite ends of the optical fiber. A thin slice of LiMgPO4 doped with Tm (1.2 mol%) crystal was exposed to the proton beam. The tested detector allowed for the measurement of proton beam current, flux fluence and determination of proton beam time structure parameters. The investigation of LiMgPO4 crystal showed its high sensitivity, fast reaction time to irradiation and possibility of application as the detector for control of proton beam parameters.

Thermoluminescence Enhancement of LiMgPO4 Crystal Host by Tb3+ and Tm3+ Trivalent Rare-Earth Ions Co-doping.

We investigated the influence of terbium and thulium trivalent rare-earth (RE) ions co-doping on the luminescent properties enhancement of LiMgPO4 (LMP) crystal host. The studied crystals were grown from the melt by micro-pulling-down (MPD) technique. Luminescent properties of the obtained crystals were investigated by thermoluminescence (TL) method. The most favorable properties and the highest luminescence enhancement were measured for Tb and Tm double doped crystals. A similar luminescence level can be also obtained for Tm, B co-doped samples. In this case, however, the low-temperature TL components have a significant contribution. The measured luminescent spectra showed a typical emission of Tb3+ and Tm3+ ions of an opposite trapping nature, namely the holes and electron-trapping sites, respectively. The most prominent transitions of 5D4 → 7F3 (550 nm for Tb3+) and 1D2 → 3F4 (450 nm for Tm3+) were observed. It was also found that Tb3+ and Tm3+ emissions show temperature dependence in the case of double doped LMP crystal sample, which was not visible in the case of the samples doped with a single RE dopant. At a low temperature range (up to around 290 °C) Tm3+ emission was dominant. At higher temperatures, the electrons occupying Tm3+ sites started to be released giving rise to emissions from Tb-related recombination centers, and emissions from Tm3+ centers simultaneously decreased. At the highest temperatures, emission took place from Tb3+ recombination centers, but only from deeper 5D4 level-related traps which had not been emptied at a lower temperature range.

Dose perturbation caused by stents: experiments with a model 90Sr/90Y source.

PURPOSE: Biological effects of intravascular brachytherapy are very sensitive to discrepancies between the prescription and the applied dose. If brachytherapy is aimed at in-stent restenosis, shielding and shadowing effects of metallic stents may change the dose distribution relative to that produced by the bare source. The development of new generations of stents inspired us to a new experimental study in this field. The effect was studied for 14 stents which we have recently encountered in clinical practice. METHODS: The model source was a continuous 20-mm column of (90)Sr/(90)Y solution sealed in a 1-mm-I.D. Plexiglas capillary. The dose distribution in the Plexiglas phantom was mapped using GafChromic MD-55-2 film. The stent masses varied from 2.5 to 25 mg; the strut thicknesses, from 0.075 to 0.15 mm; and the atomic numbers of stent materials, from 24 (Cr) to 79 (Au). RESULTS: Dose perturbations depend on a variety of stent features. Local reduction of the mean dose rates near the reference distance (r(0) = 2 mm) varied from 11% to 47%. No simple correlation was found between these data and stent characteristics, but it seems that the atomic number of the stent material is less important than the strut thickness and mesh density. CONCLUSION: The results provide a warning that clinical indications for in-stent radiation therapy must always be confronted with another aspect of the patient's history: the kind of implanted stent. Intravascular brachytherapy using pure beta sources may be recommended only for patients "wearing" light, thin-strut stents. The presence of thick-strut stents is a contraindication for this modality, due to excessive dose perturbation.